gip vs glp-1 The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology 🔗 https://bit.ly/4p18nLz Curious how GLP-1

SURPASS-4, a multicenter open-label RCT comparing treatment with tirzepatide and insulin glargine in T2D patients at increased CV risk for a median of 85 weeks, was the only study in the SURPASS program to include the change from baseline in eGFR and UACR and occurrence of eGFR decline of at least 40%, renal death, progression to end-stage kidney disease or new-onset MA among the prespecified analyses [48]

This makes it a cleaner compound for studying GLP-1 specific mechanisms but a less comprehensive tool for multi-pathway metabolic research

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given Glucagon-Like Peptide-1 (GLP-1) receptor agonists

GLP-1 receptor agonists, such as Wegovy, which contain the active ingredient semaglutide, are a class of medications widely used for obesity and type 2 diabetes